Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in

Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 77.9 EUR -1.52% Market Closed
Market Cap: €754.1m
Write Note Create Alert Ask AI

Wall St Price Targets

PHN Price Targets Summary
Pharmanutra SpA

Wall Street analysts forecast PHN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PHN is 96.22 EUR with a low forecast of 92.92 EUR and a high forecast of 102.9 EUR.

PHN Lowest Forecast
Wall Street Target
€92.92
19% Upside
PHN Average Forecast
Wall Street Target
€96.22
24% Upside
PHN Highest Forecast
Wall Street Target
€102.9
32% Upside
Lowest Forecast
Price Target
92.92 EUR
19% Upside
Average Forecast
Price Target
96.22 EUR
24% Upside
Highest Forecast
Price Target
102.9 EUR
32% Upside
Pharmanutra SpA Competitors:
Price Targets
I
INCOAX
InCoax Networks AB
74% Upside
NRG
NRJ Group SA
60% Upside
I
INCOAX
InCoax Networks AB
74% Upside
NRG
NRJ Group SA
60% Upside

Revenue
Forecast

17% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
17% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 9 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 9%.

What are analyst estimates?

Gross Profit
Forecast

17% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
17% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 9 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 3 years is 16%.

What are analyst estimates?

Operating Income
Forecast

19% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat
19% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat

Over the last 9 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 8 years is 9%.

What are analyst estimates?

Pre-Tax Income
Forecast

20% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
20% / Year
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 20%. The projected CAGR for the next 3 years is 20%.

What are analyst estimates?

Net Income
Forecast

20% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
20% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

Over the last 9 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 22%.

What are analyst estimates?

Continue PHN Research

Summary
PHN intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHN stock valuation using valuation multiples.
Wall St Estimates
PHN price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Pharmanutra SpA listings:
F • EUR
761
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is PHN's stock price target?
Price Target
96.22 EUR

According to Wall Street analysts, the average 1-year price target for PHN is 96.22 EUR with a low forecast of 92.92 EUR and a high forecast of 102.9 EUR.

What is the Revenue forecast for Pharmanutra SpA?
Projected CAGR
9%

Over the last 9 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 9%.

What is the Gross Profit forecast for Pharmanutra SpA?
Projected CAGR
16%

Over the last 9 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 3 years is 16%.

What is the Operating Income forecast for Pharmanutra SpA?
Projected CAGR
9%

Over the last 9 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 8 years is 9%.

What is the Pre-Tax Income forecast for Pharmanutra SpA?
Projected CAGR
20%

Over the last 9 years, the compound annual growth rate for Pre-Tax Income has been 20%. The projected CAGR for the next 3 years is 20%.

What is the Net Income forecast for Pharmanutra SpA?
Projected CAGR
22%

Over the last 9 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 22%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett